HopeStage
Back to all studies
CompletedNCT00204347

Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder

It focuses on personality disorders and currently lists study information in the United States.

Personality disorders, Borderline personalityDrugOver 19 Years
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 19 years.

Listed locations
Birmingham, United StatesSee all locations and recruitment

Compensation and expense reimbursement have not been verified for this summary.

Study clarity

Study information

Study start dateJuly 2003
Recruitment status
Completed
Enrollment listed in the registry
20
Sponsor
University of Alabama at Birmingham
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 19 Years
Official registry ID
NCT00204347
Official title
Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham

Registry details
Registry conditions (original wording)

Borderline Personality Disorder

FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Alabama at Birmingham, a university.

Did this study involve medication?

Yes. The study involved medication, including risperidone.

Who was this study for?

Listed age limits: from 19 years.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me